Development of Transferosomes Gel for co-delivery of Clindamycin Metronidazole against Umbilical Cord Infection

Abstract

Abstract

Neonatal sepsis is the third leading cause of deaths for infants in their first month of life. The newly cut umbilical cord can be a pathway for bacteria that can cause newborn sepsis and Clindamycin and metronidazole were chosen as the drugs of choice because they provide anaerobic coverage, treatment of severe skin and soft tissue staphylococcal infection, are both effective against aerobic and anaerobic streptococci, and metronidazole has antiprotozoal and amebicide properties. Orally and parentally administrated clindamycin has been associated with severe colitis (inflammation of large intestine) which may result into death having short half-life, high dosing frequency and high protein binding 64-90%. Transferosomes were prepared by thin film hydration method and the key materials used were Drugs (CLINDA and METRO), Phospholipids (Phospholipon 90G) and Tween-80 and Span-80 (Edge Activator). Both the Drugs, Lipid and Edge activator were optimized quantitatively using Design Expert version 12, Box Behnken model. Response variables were Particle size, Zeta potential and Entrapment efficiency. The results indicated that the optimized formulation showed 89% Entrapment efficiency for METRO and 83% EE for CLINDA, vesicle size about 173.5nm and Zeta potential of -25.6mv. Moreover, the Transferosomal formulation show sustain drug release as compare to raw drug suspension, drug release followed more sustained pattern when transferosome formulation was loaded into hyaluronic based Carbopol gel

Overall, it can be concluded that Transferosome had proven to be an efficient formulation for transdermal drug delivery of more than one drugs.